Journal of Psychopharmacology

Indexes Volume 6 1992

RM 315 .J58

Digitized by the Internet Archive
in 2026

https://archive.org/details/journal-of-psychopharmacology-uk_1992_6_index

©1993 British Association for Psychopharmacology

Author Index Volume 6 1992

(a) and A indicate abstract, only first authors on abstracts are included in this index

Abou-Saleh, M.T. 122 (a), 304
Ahlenius, S. A11
Ahlers, S.T. A68
Akiskal, H.S. 156
Al-Naser, H. 27, 139 (a), A68
Alford, C.A. 132 (a), 198, A7
Altman, H.J. A85
Amalric, M. A49
Amir-Rahmat, F. 395
Amsterdam, J.D. 167
Andersen, P.H. 43
Anderson, I.M. 120 (a), A29
Andersson, A. 509
Andrews, J.S. A35
Angst, J. A4
Anisman, H. 8
Annett, L.E. A48
Antoniou, K. A63
Aranko, K. A34
Arnsten, A.F.T. A47
Arnt, J. A62
Ashcroft, G.W. 157, A3
Ashwood, T.J. 519
Atiya, Z.H. A63
Ator, N.A. A34
Azcona, O. 136 (a), A25

Bailey, J.E. 101 (a), A21
Bailey, S.J. A5
Baker, H.F. A47
Bancroft, J. A1
Barber, D. 27
Barlow, D.H. 483
Barnard, E.A. A39
Barnes, J.M. 108 (a)
Barnes, T.R.E. 214
Barnfield, A.M. A10
Barrett, J.E. A42
Barwell, F. 198
Bayés, M.C. A36
Becker, A. A57
Becker, T. 273
Beninger, R.J. 34
Benwell, M.E.M. A9
Berendsen, H.H.G. A53
Best, N.R. 483
Biró, É A69
Bluthé, R.M. A70
Bond, A.J. A30
Bourin, M. 345
Bourne, M. A27
Bradford, L.D. 123 (a)
Bradwejn, J. A88, 345
Brady, J.V. A51
Braff, D.L. 176
Braszko, J.J. A70
Bratt, A. A58
Brett, R.R. A77
Bridges, P.K. 145, 172
Brown, V.J. A43
Bruhwyler, J. A65
Bubser, M. A66
Buckland, P.R. 115 (a), 364
Buffum, J.C. A2
Butelman, E.R. A19

Caine, S.B. A79, 142 (a), 176
Callingham, B.A. A3
Calvert, J. 103 (a)
Camanni, S. A31
Caprioli, A. A57
Carey, G.J. 140 (a)
Carli, M. A6
Cervini, M.A. A57, A58
Cestari, V. A65
Chandler, C.J. 117 (a), A65
Changeux, J.P. A39
Cheeta, S. A14
Childs, P. A28, 534
Chipkin, R.E. A32
Chleide, E. A60
Choi, P.Y.L. 135 (a)
Christensson, E.G. A32
Clarke, D. A70
Clarke, P.B.S. A39
Clincke, G.H.C. A38
Clow, A. 103 (a)
Cöuetoux du Tertre, A. 345
Cohen, C. A72
Collins, P. A50
Commissaris, R.L. A20, A72
Connick, J.H. 135 (a)
Cooper, S.J. 27, 104 (a), A83
Coppen, A. 289, 342
Corn, T. 543, 544
Costall, B. 109 (a)
Coull, J.T. A24
Coupland, N.J. A22
Couture, L.J. 410
Cowen, P.J. 158, 483
Creaney, W. 120 (a)
Cross, A.J. 370
Cunningham, K.A. A42
Curran, H.V. 69, A24, 548
Currie, D. A25

Cutler, M.G. A18
Cutts, A.J. 105 (a)

Daly, S.A. 50, A32
Das, I. 124 (a), A21, 389
Davis, M. A46
Dawe, S. A81
de Belleroche, J. 389
De Roeck, J. A6
de Roza Davis, J.M. 118 (a)
de Koning, P. A29
De Souza, R.J. 370
Deakin, J.F.W. 98
Deckert, J. 273
Dennes, R.P. A70
Depoortere, R.Y. A74, A79
Didriksen, M. A64
Dobbins, S.E. 131 (a), 132 (a)
Dodd, F. A63
Doherty, P.C. A11
Domeney, A.M. A4
Domino, E.F. 418
Donát, P. A56
Dorow, R. 382
Dourish, C.T. A88
Duggan, C.F. 300
Duka, T. 382
Dunbar, G.C. 121 (a), A27
Durcan, M.J. A19
Dursun, S.M. A10
Dworkin, S.I. A41

Ebmeier, K.P. A44
Eccleston, D. 162
Edelmann, V. 382
Edwards, J.G. 191, 204
Ekman, A.C. A22
Ellenbroek, B. A41
Elmer, G.I. A75
Emmett-Oglesby, M.W. A90
Emrich, H.M. 265
Ensler, K. A54
Eriksson, A. 509
Ervin, F. 345
Essali, M.A. 389, 453
Evans, S.M. A77
Evenden, J.L. A13, A53, A54

Fairweather, D.B. A25
Fell, G.L. 129 (a)
Fichte, K. 382
Field, M.J. A76
File, S.E. 76, 81, 258, A2, A4
Fischman, M.W. A90
Flores, P. A64
Foltin, R.W. A83
Foreman, M. A1, A53
Foster, A.C. A37
Francis, J. 27, A82
Francis, P.T. A6
French, N. A19
Frith, C.D. 436
Fritze, J. 273
Furth, W.R.v. A11

Galzigna, L. 114 (a)
Garcha, H.S. A62
Gartside, S.E. 128 (a), A17
Geddes, J. 278
Gershon, S. 514
Gewiss, M. A75
Geyer, M.A. 176, A49, 550
Gheorvassaki, E.G. A71
Gibson, E.L. A52, A83
Gilburt, S.J.A 133 (a)
Giller, E.L. 532
Girdler, N.M. 81
Glen, A.I.M. A26
Glen, I. 330
Glue, P. 102 (a), 106 (a), A22, 376
Gobert, A. A54
Goldberg, J.P. A11
Goodwin, G.M. 312
Goudie, A.J. 131 (a), A22
Gower, A.J. 128 (a), A55
Grahame-Smith, D.G. 462
Grasby, P. A45
Gray, N.S. 112 (a), A45, A60
Gray, R.W. A10
Graybiel, A.M. A81
Grecksch, G. A71
Green, A.R. 370
Grigoryan, G.A. A58
Guang, W. A55
Gyertyán, I. A56

Hall, F.S. A12
Hallstrom, C. A3, 519
Handley, S.L. A2
Haroutunian, V. A86
Harrison, A.A. A59
Hartley, J.E. 106 (a), A83
Hascoët, M. 129 (a)
Hastings, M.H. A28
Hauber, W. A43
Hawkins, D.F. 225
Healy, D. 117 (a), A29, 425, 444
Hemby, S.E. A82
Hendrie, C.A. 125 (a), A73, A78, A84
Hijzen, T. A56
Hill, J.L. 489
Hindmarch, I. 198
Hinks, G. A71
Hirsch, S.R. 389, 453
Hökfelt, T. A39
Hockney, R.A. A16
Hoffbrand, A.V. 222
Hoffer, B.J. A40
Holloway, F.A. A76
Hooks, M.S. A79

Horváth, K. A74
Hsiao, J.K. 501
Hunter, A.J. A36

Idzikowski, C. A7

Jackson, A. A76
Jackson, D.M. A37
Jäkälä, P. A59
James, M. A24
Johnson, F.N. 325
Jones, J.G. 399
Jones, M. 543
Jönsson, B. A26
Jordan, S. A20
Joseph, M.H. 98, A8
Joyce, E.M. A36
Justice, J.B.Jr. A91

Kalliteraki, I. A51
Kanellakis, K. A12
Kaye, W.H. A30
Kelley, A.E. A31
Kelly, C. A20
Kelly, J.P. A13, A14
Kemp, J.A. A33
Kennett, G.A. A51, A76
Kenyon, P. 138 (a)
Keppel Hesselink, J.M. A27
Kerr, J.S. 198, A25
Kerwin, R. 230
Keseberg, U. A61
Kihlstrom, J.F. 410
Kilbey, M.M. A81
Killcross, A.S. A67
King, D.J. 519, 547
Koch, H.J. A23
Kolb, L.C. 11
Koob, G.F. A81
Koszycki, D. 125 (a), 345
Kozak, W. A15
Kretschmer, B.D. A62
Kršiak, M. A85
Krystal, J.H. 12
Ksir, C. A9
Kulikov, A.V. A55

Lader, M.H. 357
Lanczik, M. 273
Lappas, S. 352
Lavicky, J. A89
Laviola, G. A78
Lee, A.S. 300
Levin, E.D. A7
LeWitt, P.A. 514
Lightman, S.L. A87
Lister, R.G. 133 (a)
Livingston, M.G. 519
Londei, T. A77
Lucey, J.V. 127 (a)

Malizia, A.L. 107 (a), 121 (a), 145, 172, A15
Manji, H.K. 164, 501
Mannion, M.F. 102 (a), A34
Marcusson, J. 509
Mariathasan, E.A. A8
Markou, A. A90
Marsden, C.A. A2
Marshall, J. A80
Marston, H.M. A80
Martin del Campo, A.F. 134 (a)
Martinez, J.L. Jr. A38
Martinez, R. 489
Mason, S.B. A68
Matfield, M.J. A85
Mazurkiewicz, M. A60
McAlonan, G.M. A58
McBlane, J.W. A9
McCreadie, R.G. 519
McCulloch, J. A44
McEntee, W.J. A48
McGregor, I.S. A72, A80
McGuffin, P. 364
McLaughlin, D.P. A59
McLernon, S. 136 (a)
McNaughton, N. 88
Mellow, A.M. 489
Micheau, J. A87
Miczek, K.A. A47
Mirza, N. A13
Mitchell, I.J. A43
Mitchell, P.J. 141 (a), A84, 241
Mittleman, G. A48
Moffoot, A. 109 (a)
Molchan, S.E. 489
Montgomery, A.M.J. A80
Montgomery, D.B. A27
Montgomery, S. A26, 441
Moore, N.A. 137 (a), A66
Moore, N.C. 514
Moore, S.L. 137 (a), A66
Moran, P.M. A5, A60, A61
Moreau, J.-L. A13
Morgan, M.J. A82
Morris, D.A. 139 (a), A10
Morris, R.G.M. A37
Morton, S.V. 130 (a), 357
Moser, P.C. A32
Moslehi, M. 395
Motamedi, F. 526
Moukhles, H. A44
Muir, J.L. A35
Müller, T. 273
Munglani, R. 399
Murphy, D.G.M. A45
Murphy, D.L. A3
Murray, R.M. A41, 300
Muscat, R. 114 (a), A15, 352

Negri, L. A74
Neill, J.C. 123 (a)

Nemeroff, C.B. A87
Newman, J.D. A84
Nielsen, E.B. 43
Nieoullon, A. A42
Nikulina, E.M. A64
Nutt, D.J. 376, 441, 536

O'Carroll, R.E. 109 (a)
O'Donovan, M.C. 129 (a), 364
O'Flynn, K. 119 (a)
O'Keane, V. 119 (a)
Oakley, N.R. 113 (a)
Oldman, D. A16
Olivier, B. A46
Ongini, E. 61
Osman, O.T. 501
Owen, A.M. A24

Pache, D. 134 (a)
Page, K.J. A59
Palazidou, E. A16
Palmour, R. 345
Papp, M. 116 (a), 352
Parrott, A. 541
Pattichis, K. A16
Paulus, M.P. 138 (a), A49
Pedro, B.M. A67
Peet, M. 104 (a), 160, A26, 278, 334
Peeters, B.W.M.M. A89
Peters, S.L. 110 (a)
Phillips, G.D. 115 (a), A50
Pilowsky, L.S. A33
Piot, O. 124 (a), A69
Platt, S. 291
Porrino, L.J. A41
Potter, W.Z. 164, 501
Power, A.C. A17
Preston, G.C. A5
Pretsell, D.O. A43
Pucilowski, O. A78

Quitkin, F.M. A4

Rattenbury, J.M. 278
Rawlins, J.N.P. A40
Reavill, C. A50
Redfern, P.H. 241, 546
Rees, G. A61
Rees, M.P. 483
Reibaud, M. A61
Reynolds, G. 278
Ridley, R.M. A38
Rietveld, W.J. A28
Rijnders, H.J. A62
Riley, A.J. A1
Risby, E.D. 501
Rivet, J.-M. A54
Roberts, A.C. A47
Robledo, P. A79
Rodgers, R.J. 122 (a), A52, A84
Rodin, I. 534
Rose, J.E. 545, A8
Rosenzweig, M.H. 167
Rosenzweig-Lipson, S. A64
Roushan-Zamir, F. 395
Rudorfer, M.V. 501
Rupniak, N.M.J. A48, A88
Ryan, C. A12, A31, A53, A63

Sagar, H.J. A34
Sahakian, B.J. 548, A38
Sahgal, A. A36, 549
Saiz-Ruiz, J. A18
Sakellariou, A. A51
Salmon, P. 1, 15
Sánchez, C. A73
Sanger, D.J. 141 (a), A46
Sarter, M. A86
Sattari-Naeini, M. 526
Sauer, H. 105 (a)
Schmidt, W.J. A66
Schreiber, R. A52
Schütt, B. 382
Schwartz, J.C. A37
Seale, T. A52
Sedvall, G. A44
Semple, J. A23
Serra, G. A49
Seth, R. 281
Shaffer, J. 76
Sharma, R. 76
Sharpley, A.L. 101 (a), A7
Shepherd, J.K. A56
Sherwood, N. A8
Shoaib, M. A9, A75
Silverstone, P.H. 130 (a), 462
Singh, A. A15
Singh, L. A88
Sirviö, J.S.I. A87
Skelly, A.M. 81
Skingle, M. A19
Smith, A. 281
Smith, A.P. 116 (a), 376
Smith, J.E. A89
Södersten, P. A82
Spealman, R.D. A42
Srivastava, S.K. 118 (a)
Stanford, S.C. 1, 15
Starr, B.S. A55
Stephens, D.N. A33, A40
Stinson, D. 281
Stolerman, I. 545
Šulcová, A. A73
Sunderland, T. 489
Swerdlow, N.R. 176, A40
Sykes, E.A. A18

Tai, C.T. 111 (a)
Tarrasch, R. 111 (a)

Taylor, A. A29
Terranova, M.L. A71
Thakore, J. A21
Theofilopoulos, N. A17
Thiébot, M.H. A46
Thomas, D.N. A18
Thompson, C. 281, 534
Tidswell, P. A23
Todd, C.J. 318
Tornatzky, W. A72
Trampus, M. 61
Tripp, G. 88
Tscherne, U. 265
Turner, J.J. A35, A86

Van Delft, A.M.L. 126 (a)
Veys, P.A. 222
Vidal, C. A35
Viitamaa, T. A20
Vitiello, B. 489

Waddington, J.L. 50, A31
Walsh, A.E.S. 117 (a), A30
Warburton, E.C. 110 (a)
Ward, B. 127 (a)
Wedlock, P. A73
Weerts, E.M. A85
Weingartner, H. 489
Weiss, B. A45
Wenk, G.L. A86
Wesnes, K.A. 108 (a), A23
Wheal, H.V. 204
Wilkes, S. 222
Williamson, D.J. 20
Willner, P. 140 (a), A14, 352
Wilson, C.A. A1
Wilson, S.J. 107 (a), 376, A17
Winger, G. A89
Winn, P. A50
Winnicka, M.M. A69
Wirz-Justice, A. A28
Wiśniewski, K. A69
Wogar, M.A. A5
Wolf, R. 265
Wolgin, D.L. A68
Wolterink, G. A78
Woolverton, W.L. A90
Wright, I.K. A12

Yasar, S. A75
Yavich, L. A74
Yehuda, R. 532
Young, A. 126 (a)
Young, A.H. 20
Young, A.M.J. 112 (a), 113 (a)

Zacharko, R.M. 8
Zadow, B. A65
Zarrindast, M.R. 395, 526

Subject Index Volume 6 1992

A=section in Abstract Book

Abuse
- steroid 20
Addiction
- steroid abuse 21
Adrenoceptor
- pharmacology of A18
β-Adrenoceptor
- function in resistance to stress 4, 12, 15
Affective disorders
- calcium channels 470
- circadian rhythms A28, 549
- effects of treatment on mortality in 312
- management of treatment-resistant 145, 157, 158, 160, 162, 164, 167, 172
Alcohol dependence
- calcium channels 470
Alcohol withdrawal
- effects of nimodipine and flunarizine 273
Altered consciousness
- pharmacology and phenomenology 399–440
Alzheimer's disease
- calcium channels 470
- effects of TRH and scopolamine 489
Amnesia
- lack of effect of ZK 93426 on scopolamine-induced 382
Anabolic–androgenic steroids
- abuse of in men 20
Antidepressants
- acute and chronic treatments in social behaviour of rats 241
- differential responses of new and old A26
- measurement of the behavioural toxicity 198
Antipsychotics
- clinical assessment of the extrapyramidal side effects 214
- searching for new approaches to therapy A31, 550
Anxiety
- benzodiazepines A21
- cholecystokinin hypothesis of 345
- 5-HT drugs A2
- neuropeptides A87
- psychopharmacology of A71
Anxiolytics
- behavioural analysis of novel drugs A46
Appetite
- psychopharmacology A82
Apomorphine
- effect of on retrieval in mice 528
- feeding behaviour 27
- growth hormone response to in women 483
- induced licking in rats 395
Assessment
- methods of assessing unwanted effects of psychotropic drugs 191–229

Attention
- effects of a secondary task and lorazepam 258
- effects of idazoxan on 376
Awareness
- in general anaesthesia 410
- chemical dissociation: focus on non-competitive NMDA receptor antagonists 418

Behaviour
- adaptation to stress 8
- D-1/D-2 studies 50
- neuropeptides A68
Benzodiazepines
- anxiety A21
- effects of flumazenil on symptoms persisting after withdrawal 357
- levels of GABA-A receptor subunit mRNA in rat brain 364
- lorazepam-induced amnesia 76
- memory function, alertness and mood in long-term users 69
- partial agonists A33
Brain
- consciousness and information processing 436
- [^{3}H]paroxetine binding sites in brains of suicide victims 510
Bromocriptine
- effect of on retrieval in mice 528

Calcium channels
- psychiatric disorder 462
Calcium mobilization
- in platelets from schizophrenic and healthy subjects – regulation by lithium and neuroleptics 389
Chlordiazepoxide
- effects on acquisition of DRL and signalled DRL 88
Chlorimipramine
- neuroendocrine responses to challenge of after ECT 501
Chlormethiazole
- studies on the enhancement of 5-HT-mediated behaviour by 370
Cholecystokinin
- panic and anxiety disorders 345
Chronic depression
- management and treatment of 157
Circadian rhythm
- affective disorders A28, 549
Clozapine
- reduction of dyskinesias and psychiatric disability with 514
Cocaine
- calcium channels 470
- neurobehavioural pharmacology of abuse A41

Cognition
- 5-HT A4, 547
- psychopharmacology of A57
- scopolamine, cognition and dementia (meeting report) 541
Cognitive enhancers
- the current status A38, 552
Cognitive performance
- effects of a secondary task and lorazepam 258
- effects of TRH and scopolamine 489
Cognitive psychopharmacology A23, A34, 551
- in primates A47
Consciousness
- information processing and brain 436

Dependence
- neural basis of A81
Dementia
- scopolamine, cognition and dementia (meeting report) 541
Depression
- alternative views on the pathogenesis of 441
- neuropeptides A87
- prediction of long-term outcome 300
- psychopharmacological models of A12
- psychopharmacology of A15
Des-enkephalin gamma endorphin
- effect of on melatonin secretion in healthy males 281
Dissociation
- checklist 435
- chemical dissociation of human awareness 418
Dopamine
- dependent functions in the striatum A48
- drug discrimination 43
- effect of antagonists on retrieval in mice 528
- effect of oestradiol treatment on dopamine-mediated neuroendocrine responses 483
- psychopharmacology A63
- sleep and waking states 61
- schizophrenia 230, 456
D-1 dopamine receptor
- drug discrimination 43
- effect of receptor stimulation on memory retrieval in mice 526
- feeding behaviour 27
- modulation of sleep and waking states 61
- potentiation of licking in rats by stimulation of both D-1 and D-2 dopamine receptors 395
- reward-related learning 34
- topography of unconditioned motor behaviour 50
D-2 dopamine receptor
- effect of receptor stimulation on memory retrieval in mice 526
- potentiation of licking in rats by stimulation of both D-1 and D-2 dopamine receptors 395
- topography of unconditioned motor behaviour 50
DRL and signalled DRL
- naloxone and chlordiazepoxide: effects on acquisition of 88

Drug development
- from molecular biology to psychopharmacology A37, A39
Drug discrimination
- D-1 receptor 43
Drugs of abuse A74

Eating disorder
- impulse control A29
ECT
- does not enhance neuroendocrine responses to serotonergic challenge 501
Electroencephalogram (EEG)
- D-1 receptor 61
Epileptogenic potential
- assessment of 204
Episodic memory
- tests of 77
- midazolam-induced impairment 81
Ethopharmacology
- anxiety and defence A84
Extrapyramidal side effects
- of antipsychotic drugs 214

Feeding behaviour
- dopamine D-1 receptor 27
Flumazenil
- effects of on symptoms persisting after benzodiazepine withdrawal 357
- retrieval impairments 81
Flunarizine
- in alcohol withdrawal 273
Flurazepam
- levels of GABA-A receptor subunit mRNA in rat brain following flurazepam treatment 364
Frontal cortex
- schizophrenia 230

GABA
- levels of GABA-A receptor subunit mRNA in rat brain following flurazepam treatment 364
- valproate effects on pre-optic release 265
Gating
- sensorimotor of the startle reflex 176
- deficits 177
General anaesthesia
- altered state of consciousness 399
- awareness and information processing 410
Genes
- adaptation to stress 8, 12
Growth hormone
- response to apomorphine 483

5-HT
- binding sites in brains of suicide victims 509
- cognition A4, 547
- drugs in anxiety and panic A2
- ECT does not enhance neuroendocrine responses to serotonergic challenge 501

- effect of oestradiol treatment on 5-HT-mediated neuroendocrine responses 483
- interaction with D-1 receptor 65
- mediated behaviour by chlormethiazole and phenytoin 370
- psychopharmacology A51

Hypothermia
- effect of chlormethiazole and phenytoin on 8-OH-DPAT-induced 372

Idazoxan
- effects and after-effects of on mood, memory and attention in normal volunteers 376

Impulse control
- eating disorders A29

Information processing
- consciousness and brain 436
- in general anaesthesia 410

Latent inhibition
- as model of schizophrenic dysfunction 98

Learning
- psychopharmacology of A57
- neurotransmitter interactions with cholinergic function in A85

LH
- effect of valproate on pituitary secretion 265

Licking
- potentiation of by stimulation of both D-1 and D-2 dopamine receptors 395

Lithium
- calcium mobilization in platelets – regulation by 389
- evolution of 325
- interaction with neuroleptics 457
- practical aspects of long-term treatment with 330

LNAA
- ratio of plasma phenylalanine to other LNAAs is not a risk factor for tardive dyskinesia 278

Lorazepam
- amnesia 76
- effects of on cognitive performance 258

LY 163502
- behavioural responses 52

Melatonin
- effect of des-enkephalin gamma endorphin on secretion in healthy males 281

Memory
- effects of a secondary task and lorazepam 258
- effects of idazoxan on 376
- effects of TRH and scopolamine 489
- long-term benzodiazepine users 69
- lorazepam-induced amnesia 76
- neurotransmitter interactions with cholinergic function in A85
- psychopharmacology of A57
- scopolamine-induced amnesia in humans: lack of effect of ZK 93426 382
- implicit and explicit following general anaesthesia 410

Methods
- in psychopharmacology A55

Midazolam
- retrieval impairments 81

Monoamine oxidase inhibitors A3

Mood
- long-term benzodiazepine users 69
- effects of idazoxan on 376

Morphine
- calcium channels 470
- place preference conditioning 352

Motivated behaviour
- psychopharmacology of A9

Mortality
- effect of treatment on in affective illness 312

Naloxone
- effects on acquisition of DRL and signalled DRL 88
- place preference conditioning 352

Neurochemistry
- changes from exposure to stress 1, 8

Neuroendocrine
- responses to serotonergic challenge 501

Neuroimaging
- psychopharmacology of A44

Neuroleptics
- calcium mobilization in platelets – regulation by 389
- interaction with lithium 457
- receptor-mediated effects of on the PI system 453

Neuropeptides
- behaviour A68
- in stress, anxiety and depression A87

Nicotine
- psychopharmacology A7, 548

Nimodipine
- in alcohol withdrawal 273

NMDA receptor antagonists
- chemical dissociation of human awareness 418

NMR
- assessment of brain function 456

Noradrenaline
- black bile and noradrenaline: alternative views on the pathogenesis of depression (meeting report) 441
- in resistance to stress 2, 12

Nucleus accumbens
- reward 30

Oestradiol
- effect on 5-HT- and dopamine-mediated neuroendocrine responses 483

Outcome
- prediction of hospitalized depressives 300

Panic
- cholecystokinin hypothesis of 345
- 5-HT drugs A2

Parasuicide
- epidemiology of 291

Paroxetine
- radioligand in brains of suicide victims 509

Phenylalanine
- ratio of plasma phenylalanine to other LNAAs is not a risk factor for tardive dyskinesia 278
Phenobarbitone
- lack of effect on 5-HT behavioural syndrome 370
Phenytoin
- studies on the enhancement of 5-HT-mediated behaviour by 370
Phosphoinositide
- dopamine D-2 receptors 454
- effects of lithium and neuroleptics on 457
- link between receptors and intracellular calcium 453
Picrotoxin
- place preference conditioning 352
Place conditioning
- dopamine agonists 38
- effects of chronic mild stress 352
Place preference
- attenuation of by chronic mild stress 352
Platelets
- calcium mobilization in schizophrenic and healthy subjects 389
Post-traumatic stress disorder (PTSD)
- neurochemical research 11
Pre-optic
- GABA release 265
Pre-pulse inhibition
- pharmacology and anatomy of 178
Priming
- tests in midazolam-sedated dental patients 83
Prolactin
- response to L-tryptophan 483
Psychiatric disorder
- and calcium channels 462
Psychomotor tests
- long-term benzodiazepine use 70
- lorazepam 76
Psychopharmacology
- big business or successful science (meeting report) 444
Psychotropic drugs
- methods of assessing unwanted effects 191 –229

Quinpirole
- effects of on licking behaviour in rats 395
- effect of on retrieval in mice 528

Receptor occupancy
- dopamine in binding studies 44
Recurrent mood disorder
- prevention of suicide in 334
Remoxipride
- an open study of in the long-term treatment of schizophrenia 519
Reserpine
- effects of on licking behaviour in rats 395
Resistance
- to stress 1, 8, 11, 12, 15, 532
Resistant depression
- the management and treatment of 145, 157, 158, 160, 162, 164, 167, 172, 534
Retrieval
- effect of D-1 or D-2 receptor stimulation on memory retrieval in mice 526
- midazolam-induced impairments revealed by flumazenil 81
Reward-related learning
- D-1 receptor involvement 34
mRNA
- levels of GABA-A receptor subunit mRNA in rat brain following flurazepam treatment 364

SCH 23390
- reward-related learning 34
SCH 39166
- reward-related learning 34
Schizophrenia
- aspects of (meeting report) 444
- calcium channels 470
- calcium mobilization in platelets – regulation by lithium and neuroleptics 389
- dopamine hypothesis 456
- frontal and temporal lobe aspects of the neuropharmacology of 230
- latent inhibition and other paradigms as models of dysfunction 98
- open study of remoxipride in 519
- ratio of plasma phenylalanine to other LNAAs is not a risk factor for tardive dyskinesia 278
- psychopharmacology of (meeting report) 536
- psychopharmacological models A40, 553
- sleep 538
Scopolamine
- cognition and dementia (meeting report) 541
- effects of in Alzheimer's disease and volunteers 489
- lack of effect of ZK 93426 on scopolamine-induced amnesia in humans 382
Self-administration
- current status of research A89
- dopamine agonists 36
Semantic memory
- tests of 77
- midazolam-induced impairment 81
Sensorimotor gating
- of the startle reflex, a review of recent findings 176
Sensorimotor integration
- psychopharmacology of A42
Sexuality
- the psychopharmacology of A1, 546
SKF 38393
- EEG effects 61
- effect of on retrieval in mice 528
- effects of on licking behaviour in rats 395
- feeding behaviour 28
- reward-related learning 34
SKF 77434
- behavioural responses 52
SKF 83189
- behavioural responses 50

leep
- altered state of consciousness 399
- D-1 receptors 61
- psychopharmacological aspects of A6
- schizophrenia 538
ocial interaction
- effects of acute and chronic antidepressants in rats 241
tartle reflex
- sensorimotor gating of 176
tress
- attenuation of place preference conditioning but not place aversion by 352
- neuropeptides A87
- psychopharmacological models of A12
- resistance to 1, 8, 11, 12, 15, 532
uicide
- effects of treatment on 312
- epidemiology of 291
- management of patients at risk for 304
- prevention in recurrent mood disorder 289–344
- treatment of suicidal behaviour 309
- unaltered number of brain serotonin uptake sites in suicide victims 509

ardive dyskinesia
- calcium channels 470
- ratio of plasma phenylalanine to other LNAAs is not a risk factor for 278
- reduction of with clozapine 514
Temporal lobe
- neurochemistry of in schizophrenia 234
Teratogenicity
- assessment of 225
Tolerance
- levels of GABA-A receptor subunit mRNA in rat brain following flurazepam treatment 364
TRH
- effects of in Alzheimer's disease and volunteers 489
- psychopharmacology of A21
L-Tryptophan
- prolactin response to in women 483

Valproate
- effects on pre-optic GABA release and pituitary LH secretion in the rat 265

ZK 93426
- lack of effect on scopolamine-induced amnesia in humans 382